SCHEMBL4652185

SCHEMBL4652185

Nc1c2c(c(O)c3ncccc13)C(=O)N(Cc1ccc(F)cc1)C2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
KAT2B Q92831 1/20 0.43
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 1/20 0.41
COMT P21964 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
HSP90AA1 P07900 2/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PARP1 P09874 1/20 0.40
CASP3 P42574 1/20 0.40
RPS6KB1 P23443 1/20 0.39
CNR2 P34972 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4652231 0.99 CYP1A2 (0.49) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL4150453 0.91 CYP1A2 (0.54) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL13943471 0.86 CYP1A2 (0.50) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL13943867 0.84 CYP1A2 (0.48) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL14270412 0.84 CYP1A2 (0.47) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL13943866 0.84 CYP1A2 (0.47) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL4162838 0.84 CYP1A2 (0.47) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL4150996 0.83 CYP1A2 (0.51) CYP1A2CYP2C19KAT2BL3MBTL1LMNA
SCHEMBL13943483 0.83 CYP1A2 (0.46) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1
SCHEMBL13943886 0.82 CYP1A2 (0.44) CYP1A2CYP2C19KAT2BKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973908-A2 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2008-10-01 EP disclosed
EP-1888581-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2008-02-20 EP disclosed
US-20080039487-A1 Processes and intermediates useful for preparing integrase inhibitor compounds GILEAD SCIENCES, LLC 2008-02-14 US disclosed
US-20080039487-A1 Processes and intermediates useful for preparing integrase inhibitor compounds GILEAD SCIENCES, LLC 2008-02-14 US disclosed
US-20080039487-A1 Processes and intermediates useful for preparing integrase inhibitor compounds GILEAD SCIENCES, LLC 2008-02-14 US disclosed
WO-2007076005-A2 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2007-07-05 WO disclosed
WO-2007076005-A2 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2007-07-05 WO disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
WO-2006125048-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072831-A1 Integrase inhibitor compounds TYMP, CDKN1A, PAICS CYP1A2 1685/4885CYP2C19 1140/4885KAT2B 899/4885
US-20080039487-A1 Processes and intermediates useful for preparing integrase inhibitor compounds TYMP, DUT, SAMHD1 CYP1A2 686/4885CYP2C19 349/4885KAT2B 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.